Symbols / NAMS Stock $30.25 +1.78% NewAmsterdam Pharma Company N.V.
NAMS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Ratings
Current target
$30.25
Low
$37.88
High
$61.29
Mean
$49.65
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-19 | main | Guggenheim | Buy → Buy | $45 |
| 2026-02-18 | main | Needham | Buy → Buy | $48 |
| 2026-01-21 | main | RBC Capital | Outperform → Outperform | $47 |
| 2025-12-16 | main | Stifel | Buy → Buy | $50 |
| 2025-12-02 | main | Goldman Sachs | Neutral → Neutral | $37 |
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $44 |
| 2025-11-05 | main | Needham | Buy → Buy | $46 |
| 2025-10-17 | main | Citigroup | Buy → Buy | $50 |
| 2025-08-25 | init | Wells Fargo | — → Overweight | $45 |
| 2025-08-07 | main | RBC Capital | Outperform → Outperform | $39 |
| 2025-07-17 | init | Goldman Sachs | — → Neutral | $27 |
| 2025-06-17 | init | Citigroup | — → Buy | $42 |
| 2025-06-12 | reit | Needham | Buy → Buy | $40 |
| 2025-06-10 | init | Stifel | — → Buy | $44 |
| 2025-05-08 | main | Needham | Buy → Buy | $40 |
| 2025-04-08 | reit | Needham | Buy → Buy | $42 |
| 2025-02-27 | main | Scotiabank | Sector Outperform → Sector Outperform | $52 |
| 2025-02-27 | main | Needham | Buy → Buy | $42 |
| 2025-01-28 | reit | RBC Capital | Outperform → Outperform | $40 |
| 2025-01-24 | reit | RBC Capital | Outperform → Outperform | $40 |
- NewAmsterdam Pharma (NAMS) details CAO exit, bonus and equity terms - Stock Titan Fri, 24 Apr 2026 20
- NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Yahoo Finance Wed, 08 Apr 2026 07
- NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today (NASDAQ:NAMS) - Seeking Alpha hu, 16 Apr 2026 07
- Price-Driven Insight from (NAMS) for Rule-Based Strategy - Stock Traders Daily Wed, 22 Apr 2026 14
- Does NewAmsterdam Pharma (NAMS) CETP Optimism Point To A Durable Edge In Cardiovascular Treatment? - simplywall.st ue, 07 Apr 2026 07
- Insider Sale: Chief Scientific Officer of $NAMS Sells 6,000 Shares - Quiver Quantitative Wed, 07 Jan 2026 08
- NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) posts wider than expected Q4 2025 loss, shares rise 4.46 percent on upbeat investor sentiment. - Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 01
- NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews ue, 24 Feb 2026 08
- The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering - Yahoo Finance Mon, 23 Feb 2026 08
- A cholesterol pill's kidney and safety data head to a major heart meeting - Stock Titan Mon, 23 Mar 2026 07
- A Look At NewAmsterdam Pharma (NAMS) Valuation After Positive Obicetrapib Trial Sentiment And ACC.26 Data Presentations - simplywall.st Sun, 05 Apr 2026 07
- Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance Wed, 14 Jan 2026 08
- Two new hires get 15,000 stock options and 3,200 RSUs at NewAmsterdam - Stock Titan hu, 02 Apr 2026 07
- NewAmsterdam Pharma CFO joins Needham healthcare event on Apr. 13 - Stock Titan Wed, 08 Apr 2026 07
- A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results - Yahoo Finance hu, 09 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
22.50
-50.61%
|
45.56
+223.37%
|
14.09
-86.28%
|
102.69
|
| Operating Revenue |
|
22.50
-50.61%
|
45.56
+223.37%
|
14.09
-86.28%
|
102.69
|
| Operating Expense |
|
248.19
+11.87%
|
221.85
+12.58%
|
197.06
+85.46%
|
106.25
|
| Research And Development |
|
141.83
-6.32%
|
151.41
-5.03%
|
159.42
+83.79%
|
86.74
|
| Selling General And Administration |
|
106.35
+50.97%
|
70.45
+87.19%
|
37.63
+92.92%
|
19.51
|
| Selling And Marketing Expense |
|
—
|
—
|
4.06
+198.04%
|
1.36
|
| General And Administrative Expense |
|
106.35
+50.97%
|
70.45
+87.19%
|
37.63
+92.92%
|
19.51
|
| Salaries And Wages |
|
—
|
—
|
17.14
+218.50%
|
5.38
|
| Other Gand A |
|
106.35
+50.97%
|
70.45
+87.19%
|
37.63
+92.92%
|
19.51
|
| Total Expenses |
|
248.19
+11.87%
|
221.85
+12.58%
|
197.06
+85.46%
|
106.25
|
| Operating Income |
|
-225.68
-28.02%
|
-176.29
+3.65%
|
-182.97
-5043.86%
|
-3.56
|
| Total Operating Income As Reported |
|
-225.68
-28.02%
|
-176.29
+3.65%
|
-182.97
-5043.86%
|
-3.56
|
| EBITDA |
|
-225.46
-27.98%
|
-176.18
+3.69%
|
-182.92
-718.86%
|
-22.34
|
| Normalized EBITDA |
|
-219.74
-133.80%
|
-93.98
+47.11%
|
-177.69
-1438.46%
|
-11.55
|
| Reconciled Depreciation |
|
0.22
+94.69%
|
0.11
+130.61%
|
0.05
+444.44%
|
0.01
|
| EBIT |
|
-225.68
-28.02%
|
-176.29
+3.65%
|
-182.97
-718.75%
|
-22.35
|
| Total Unusual Items |
|
-5.73
+93.03%
|
-82.19
-1472.73%
|
-5.23
+51.56%
|
-10.79
|
| Total Unusual Items Excluding Goodwill |
|
-5.73
+93.03%
|
-82.19
-1472.73%
|
-5.23
+51.56%
|
-10.79
|
| Special Income Charges |
|
3.99
+110.79%
|
-37.01
-13813.53%
|
-0.27
+62.38%
|
-0.71
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
-3.99
-110.79%
|
37.01
+13813.53%
|
0.27
-62.38%
|
0.71
|
| Net Income |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Pretax Income |
|
-203.82
+15.64%
|
-241.60
-36.57%
|
-176.91
-681.61%
|
-22.63
|
| Net Non Operating Interest Income Expense |
|
27.59
+63.45%
|
16.88
+49.61%
|
11.28
+4031.36%
|
-0.29
|
| Interest Expense Non Operating |
|
—
|
0.00
|
0.00
-100.00%
|
0.29
|
| Net Interest Income |
|
27.59
+63.45%
|
16.88
+49.61%
|
11.28
+4031.36%
|
-0.29
|
| Interest Expense |
|
—
|
0.00
|
0.00
-100.00%
|
0.29
|
| Interest Income Non Operating |
|
27.59
+63.45%
|
16.88
+49.61%
|
11.28
|
0.00
|
| Interest Income |
|
27.59
+63.45%
|
16.88
+49.61%
|
11.28
|
0.00
|
| Other Income Expense |
|
-5.73
+93.03%
|
-82.19
-1472.73%
|
-5.23
+72.19%
|
-18.79
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
-8.00
|
| Gain On Sale Of Security |
|
-9.72
+78.49%
|
-45.18
-810.91%
|
-4.96
+50.80%
|
-10.08
|
| Tax Provision |
|
0.00
+100.00%
|
-0.00
-103.70%
|
0.03
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-1.35
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Net Income From Continuing Operation Net Minority Interest |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Net Income From Continuing And Discontinued Operation |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Net Income Continuous Operations |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Normalized Income |
|
-198.09
-24.27%
|
-159.41
+7.89%
|
-173.06
-1360.91%
|
-11.85
|
| Net Income Common Stockholders |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Diluted EPS |
|
-1.72
+32.81%
|
-2.56
-19.07%
|
-2.15
-80.67%
|
-1.19
|
| Basic EPS |
|
-1.72
+32.81%
|
-2.56
-19.07%
|
-2.15
-80.67%
|
-1.19
|
| Basic Average Shares |
|
118.42
+25.51%
|
94.36
+14.84%
|
82.16
+333.20%
|
18.97
|
| Diluted Average Shares |
|
118.42
+25.51%
|
94.36
+14.84%
|
82.16
+333.20%
|
18.97
|
| Diluted NI Availto Com Stockholders |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.08
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.08
|
| Insurance And Claims |
|
—
|
—
|
—
|
0.31
|
| Rent And Landing Fees |
|
—
|
—
|
—
|
0.18
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
0.18
|
| Total Other Finance Cost |
|
—
|
—
|
7.86
+40.74%
|
5.59
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
347.10
|
| Current Assets |
|
346.79
|
| Cash Cash Equivalents And Short Term Investments |
|
340.45
|
| Cash And Cash Equivalents |
|
340.45
|
| Cash Equivalents |
|
—
|
| Cash Financial |
|
340.45
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
1.88
|
| Other Receivables |
|
0.88
|
| Taxes Receivable |
|
1.01
|
| Prepaid Assets |
|
4.46
|
| Restricted Cash |
|
—
|
| Total Non Current Assets |
|
0.31
|
| Net PPE |
|
0.10
|
| Gross PPE |
|
0.10
|
| Accumulated Depreciation |
|
—
|
| Machinery Furniture Equipment |
|
—
|
| Other Properties |
|
0.10
|
| Goodwill And Other Intangible Assets |
|
0.17
|
| Investments And Advances |
|
—
|
| Non Current Prepaid Assets |
|
0.04
|
| Total Liabilities Net Minority Interest |
|
58.70
|
| Current Liabilities |
|
49.90
|
| Payables And Accrued Expenses |
|
24.94
|
| Payables |
|
16.92
|
| Accounts Payable |
|
16.92
|
| Current Accrued Expenses |
|
8.01
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.38
|
| Total Tax Payable |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.06
|
| Current Capital Lease Obligation |
|
0.06
|
| Current Deferred Liabilities |
|
8.94
|
| Current Deferred Revenue |
|
8.94
|
| Other Current Liabilities |
|
12.57
|
| Total Non Current Liabilities Net Minority Interest |
|
8.81
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Non Current Deferred Liabilities |
|
1.02
|
| Non Current Deferred Revenue |
|
1.02
|
| Stockholders Equity |
|
288.39
|
| Common Stock Equity |
|
288.39
|
| Capital Stock |
|
10.17
|
| Common Stock |
|
10.17
|
| Share Issued |
|
82.47
|
| Ordinary Shares Number |
|
82.47
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
590.77
|
| Retained Earnings |
|
-316.97
|
| Gains Losses Not Affecting Retained Earnings |
|
4.42
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
288.39
|
| Total Capitalization |
|
288.39
|
| Working Capital |
|
296.89
|
| Invested Capital |
|
288.39
|
| Total Debt |
|
0.06
|
| Capital Lease Obligations |
|
0.06
|
| Net Tangible Assets |
|
288.22
|
| Tangible Book Value |
|
288.22
|
| Available For Sale Securities |
|
—
|
| Derivative Product Liabilities |
|
7.79
|
| Foreign Currency Translation Adjustments |
|
4.42
|
| Investmentin Financial Assets |
|
—
|
| Non Current Note Receivables |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-147.78
+6.80%
|
-158.56
-12.28%
|
-141.22
-1424.13%
|
10.66
|
| Cash Flow From Continuing Operating Activities |
|
-147.78
+6.80%
|
-158.56
-12.28%
|
-141.22
-1424.13%
|
10.66
|
| Net Income From Continuing Operations |
|
-203.82
+15.64%
|
-241.60
-36.54%
|
-176.94
-681.73%
|
-22.63
|
| Depreciation Amortization Depletion |
|
0.22
+94.69%
|
0.11
+130.61%
|
0.05
+444.44%
|
0.01
|
| Depreciation And Amortization |
|
0.22
+94.69%
|
0.11
+130.61%
|
0.05
+444.44%
|
0.01
|
| Other Non Cash Items |
|
—
|
0.01
+100.00%
|
0.01
-99.93%
|
8.01
|
| Stock Based Compensation |
|
59.42
+76.76%
|
33.62
+36.82%
|
24.57
+496.84%
|
4.12
|
| Operating Gains Losses |
|
5.74
-93.02%
|
82.19
+1472.73%
|
5.23
-51.56%
|
10.79
|
| Gain Loss On Investment Securities |
|
18.78
-75.15%
|
75.59
+635.05%
|
10.28
+887.90%
|
1.04
|
| Net Foreign Currency Exchange Gain Loss |
|
-13.05
-297.86%
|
6.60
+230.45%
|
-5.06
-151.89%
|
9.75
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
|
0.00
|
—
|
| Change In Working Capital |
|
-7.94
+75.69%
|
-32.67
-657.01%
|
5.87
-43.45%
|
10.37
|
| Change In Prepaid Assets |
|
-13.28
+23.94%
|
-17.46
-533.12%
|
4.03
+196.32%
|
-4.18
|
| Change In Payables And Accrued Expense |
|
7.36
+165.33%
|
-11.26
-206.85%
|
10.54
+372.35%
|
-3.87
|
| Change In Accrued Expense |
|
2.45
+45.20%
|
1.69
-69.18%
|
5.47
+163.03%
|
-8.68
|
| Change In Payable |
|
4.91
+137.91%
|
-12.95
-355.38%
|
5.07
+5.43%
|
4.81
|
| Change In Account Payable |
|
4.91
+137.91%
|
-12.95
-355.38%
|
5.07
+5.43%
|
4.81
|
| Change In Other Working Capital |
|
-2.02
+48.87%
|
-3.95
+54.59%
|
-8.71
-147.24%
|
18.43
|
| Investing Cash Flow |
|
-174.92
-178.32%
|
-62.85
-261766.67%
|
-0.02
+89.14%
|
-0.22
|
| Cash Flow From Continuing Investing Activities |
|
-174.92
-178.32%
|
-62.85
-261766.67%
|
-0.02
+89.14%
|
-0.22
|
| Net PPE Purchase And Sale |
|
-0.25
+63.39%
|
-0.67
-2700.00%
|
-0.02
+89.14%
|
-0.22
|
| Purchase Of PPE |
|
-0.25
+63.39%
|
-0.67
-2700.00%
|
-0.02
+89.14%
|
-0.22
|
| Capital Expenditure |
|
-0.25
+63.39%
|
-0.67
-2700.00%
|
-0.02
+89.14%
|
-0.22
|
| Net Investment Purchase And Sale |
|
-174.67
-180.93%
|
-62.18
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-296.73
-377.25%
|
-62.18
|
0.00
|
0.00
|
| Sale Of Investment |
|
122.06
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.78
|
| Financing Cash Flow |
|
29.52
-95.52%
|
659.51
+7300.21%
|
8.91
-97.73%
|
391.90
|
| Cash Flow From Continuing Financing Activities |
|
29.52
-95.52%
|
659.51
+7300.21%
|
8.91
-97.73%
|
391.90
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
0.75
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
0.75
|
| Repayment Of Debt |
|
—
|
—
|
—
|
-0.07
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
0.75
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
-0.07
|
| Net Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
0.75
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
645.51
|
0.00
-100.00%
|
396.95
|
| Proceeds From Stock Option Exercised |
|
31.11
+100.31%
|
15.53
+74.25%
|
8.91
|
0.00
|
| Net Other Financing Charges |
|
-1.59
-3.73%
|
-1.53
|
—
|
-5.79
|
| Changes In Cash |
|
-293.18
-166.92%
|
438.10
+431.06%
|
-132.33
-132.89%
|
402.35
|
| Effect Of Exchange Rate Changes |
|
12.76
+287.58%
|
-6.80
-234.64%
|
5.05
-3.73%
|
5.25
|
| Beginning Cash Position |
|
771.74
+126.68%
|
340.45
-27.21%
|
467.73
+677.85%
|
60.13
|
| End Cash Position |
|
491.32
-36.34%
|
771.74
+126.68%
|
340.45
-27.21%
|
467.73
|
| Free Cash Flow |
|
-148.03
+7.04%
|
-159.24
-12.74%
|
-141.24
-1452.37%
|
10.44
|
| Interest Paid Supplemental Data |
|
—
|
0.00
|
0.00
-100.00%
|
0.28
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
-96.30%
|
0.03
|
0.00
|
| Amortization Of Securities |
|
-1.41
-518.94%
|
-0.23
|
0.00
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
645.51
|
0.00
-100.00%
|
396.95
|
| Interest Paid CFO |
|
—
|
—
|
—
|
-0.28
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
645.51
|
0.00
-100.00%
|
396.95
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-24 View
- 42026-03-12 View
- 42026-03-10 View
- 42026-03-09 View
- 42026-03-02 View
- 8-K2026-03-02 View
- 42026-02-26 View
- 42026-02-24 View
- 10-K2026-02-18 View
- 8-K2026-02-18 View
- 42026-01-29 View
- 42026-01-27 View
- 42026-01-22 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|